PT-141 (10mg Vial)

01 · At a glance

Quickstart Highlights

PT‑141 (bremelanotide) is a melanocortin receptor agonist that acts centrally—predominantly via MC4R—to influence sexual desire pathways [7] [8] . The FDA‑approved subcutaneous regimen for HSDD is a single 1.75 mg injection as needed (PRN) , administered at least 45 minutes before anticipated sexual activity; do not exceed one dose per 24 hours or eight doses per month [1] . The table below presents practical per‑administration measurements using a clear insulin‑syringe dilution.

02 · Dosing & reconstitution

Dosing & Reconstitution Guide

A practical calculator-ready setup based on the imported protocol reference. Use these values as a math starting point, then verify every entry against your own vial, diluent, and professional guidance.

Standard / Gradual Titration

Reference dose shown on this page: See guide.

Reconstitution Steps

1. Using sterile technique, draw 3.0 mL bacteriostatic water.
2. Inject slowly down the vial wall; avoid foaming.
3. Gently swirl/roll until dissolved (do not shake).
4. Label and refrigerate at 2–8 °C (35.6–46.4 °F) ; protect from light [14] .

03 · What you'll need

Supplies Needed

Keep this as a planning checklist. TNHL does not sell or verify supplies on this page, and no supplier quality claims are made here.

Protocol Overview

• Goal: Improve sexual desire and reduce related distress in premenopausal women with HSDD, as shown in two Phase 3 RECONNECT trials [2] .
• Schedule: PRN subcutaneous dosing—1.75 mg at least 45 minutes before anticipated activity; limit 1 dose per 24 h and ≤8/month; reassess after ~8 weeks [1] . Per‑administration Range: 0.5–1.75 mg depending on response/tolerability, with 1.75 mg as the standard labeled dose [1] .
• Reconstitution: 3.0 mL per 10 mg vial (~3.33 mg/mL) for straightforward unit measurements.
• Storage: Lyophilized cold (≤ −20 °C / ≤ −4 °F) and reconstituted refrigerated at 2–8 °C (35.6–46.4 °F) per general biologic stability practices [13] [14] .

Dosing Protocol

• Guidance for practical, safe use with clarity on limits.
• Start & Titrate: Consider a conservative trial (e.g., 0.5–1.0 mg) and titrate toward 1.75 mg PRN based on effect and tolerability [1] .
• Do not exceed: 1 dose per 24 h or more than 8 doses per month (higher frequency increased focal hyperpigmentation in studies) [1] .
• Timing: Inject ~45–60 minutes before anticipated activity; some individuals may adjust timing based on personal response [1] .

Storage Instructions

• (general biologic handling): Lyophilized materials are commonly kept cold for long‑term stability (≤ −20 °C (≤ −4 °F) ) [13] ; reconstituted peptide solutions are commonly held refrigerated short‑term at 2–8 °C (35.6–46.4 °F) [14] . Avoid repeated freeze–thaw.
• Storage: Lyophilized cold (≤ −20 °C / ≤ −4 °F) and reconstituted refrigerated at 2–8 °C (35.6–46.4 °F) per general biologic stability practices [13] [14] .
• Keep mixed and unmixed items clearly labeled so inventory and dose logs stay accurate.

04 · Good to know

Important Notes

• Practical considerations for consistent technique and safety.
• Use new sterile insulin syringes and dispose of sharps appropriately; follow aseptic preparation [3] .
• Rotate injection sites (abdomen, thighs, upper arms) to reduce local reactions and maintain absorption [3] [11] .
• Insert at 45–90° into subcutaneous tissue; do not aspirate for SC injections [3] [4] [10] .
• Common adverse effects include nausea, flushing, headache, and transient blood‑pressure increases; consider cardiovascular risk and labeled precautions [1] .

05 · How it works

How This Works

PT‑141 (bremelanotide) is a melanocortin receptor agonist that acts centrally—predominantly via MC4R—to influence sexual desire pathways [7] [8] .

The FDA‑approved subcutaneous regimen for HSDD is a single 1.75 mg injection as needed (PRN) , administered at least 45 minutes before anticipated sexual activity; do not exceed one dose per 24 hours or eight doses per month [1] .

The table below presents practical per‑administration measurements using a clear insulin‑syringe dilution.

The library page pairs that educational context with calculator-ready vial math, so users can understand the protocol structure and then track their own entered values in one place.

06 · Daily habits

Lifestyle Factors

• Keep meals, training, sleep, and recovery notes in the journal so trends are easier to review.
• Track body metrics only if they are relevant to the user's goal and approved data sources.
• Use consistent timing and logging habits so adherence data is meaningful.

07 · What to expect

Potential Benefits & Side Effects

• PT-141 observations should be recorded conservatively: expected research endpoints, tolerability notes, injection-site reactions when applicable, sleep, appetite, energy, mood, and any adverse or unusual response.
• This section is not a claim of therapeutic benefit.

08 · Technique

Injection Technique

09 · Evidence

References